SCHEMBL23347014

SCHEMBL23347014

CCC(=O)CCCCCNC(=O)C1CCC(CN2C(=O)C=CC2=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.43
NAAA Q02083 1/20 0.42
GNAI3 P08754 2/20 0.40
GNAO1 P09471 2/20 0.40
GNAI1 P63096 2/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
TTR P02766 1/20 0.38
IL2 P60568 1/20 0.38
THRB P10828 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20936573 0.89 SMN1; SMN2 (0.42) SMN1; SMN2NAAAGNAI3GNAO1GNAI1
SCHEMBL20936656 0.89 SMN1; SMN2 (0.40) SMN1; SMN2NAAAGNAI3GNAO1GNAI1
SCHEMBL2779228 0.89 NAAA (0.55) SMN1; SMN2NAAAGNAI3GNAO1GNAI1
SCHEMBL14872066 0.89 NAAA (0.55) SMN1; SMN2NAAAGNAI3GNAO1GNAI1
SCHEMBL6849179 0.88 PTGS1 (0.47) SMN1; SMN2NAAALMNATTRIL2
SCHEMBL11990499 0.88 SMN1; SMN2 (0.53) SMN1; SMN2NAAAGNAI3GNAO1GNAI1
SCHEMBL17739999 0.88 NAAA (0.48) SMN1; SMN2NAAAGNAI3GNAO1GNAI1
SCHEMBL19703683 0.88 SMN1; SMN2 (0.43) SMN1; SMN2NAAAGNAI3GNAO1GNAI1
SCHEMBL21659263 0.87 NAMPT (0.42) SMN1; SMN2NAAAGNAI3GNAO1GNAI1
SCHEMBL4761616 0.87 SMN1; SMN2 (0.49) SMN1; SMN2NAAAGNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169660-A1 CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF SILVERBACK THERAPEUTICS INC (US) 2022-06-02 US disclosed
US-20210139477-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139477-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF ALK, ALKBH5, ACVR1 SMN1; SMN2 3664/4885NAAA 2452/4885GNAI3 1363/4885
US-20220169660-A1 CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF TGFBR2, ACVR2A, SMAD2 SMN1; SMN2 3980/4885NAAA 2192/4885GNAI3 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.